Kidney Cancer Clinical Practice Guidelines in Oncology
NCCN Categories of Evidence and Consensus
Category 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there isuniform NCCN consensus.
Category 2A: The recommendation is based on lower-level evidence and there is uniform NCCN consensus.
Category 2B: The recommendation is based on lower-level evidence and there is nonuniform NCCN consensus (but no major disagreement).
Category 3: The recommendation is based on any level of evidence but reflects major disagreement.
All recommendations are category 2A unless otherwise noted.
Clinical trials: The NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Overview
In 2008, an estimated 54,390 Americans were diagnosed with kidney cancer and 13,010 died of the disease in the United States.1 Renal cell carcinoma (RCC) comprises approximately 2% of all malignancies, with a median age at diagnosis of 65 years. The rate of RCC has increased 2% per year for the past 65 years. The reason for this increase is unknown. Approximately 90% of renal tumors are RCC, and 85% of these are clear cell tumors.2 Other, less-common cell types include papillary, chromophobe, and Bellini (collecting) duct tumors. Collecting duct carcinoma comprises fewer than 1% of all cases. Medullary renal carcinoma is a variant of collecting duct renal carcinoma and was initially described as occurring in patients who are sickle cell–trait positive.
Smoking and obesity are among the risk factors for RCC development. Several hereditary types...
If the inline PDF is not rendering correctly, you can download the PDF file here.
RiesLAG, MelbertD, KrapchoM, eds. SEER Cancer Statistics Review, 1975–2004, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER web site, 2007.
RiesLAGMelbertDKrapchoM, eds. SEER Cancer Statistics Review, 1975–2004, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER web site, 2007.
)| false
HricakH, DemasBE, WilliamsRD. Magnetic resonance imaging in the diagnosis and staging of renal and perirenal neoplasms. Radiology1985;154:709–715.
HricakHDemasBEWilliamsRD. Magnetic resonance imaging in the diagnosis and staging of renal and perirenal neoplasms. Radiology1985;154:709–715.
)| false
DechetCB, ZinckeH, SeboTJ. Prospective analysis of computerized tomography and needle biopsy with permanent sectioning to determine the nature of solid renal masses in adults. J Urol2003;169:71–74.
DechetCBZinckeHSeboTJ. Prospective analysis of computerized tomography and needle biopsy with permanent sectioning to determine the nature of solid renal masses in adults. J Urol2003;169:71–74.
)| false
LeibovichBC, BluteML, ChevilleJC. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol2004;17:1066–1070.
LeibovichBCBluteMLChevilleJC. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol2004;17:1066–1070.
)| false
RouviereO, BouvierR, NegrierS. Nonmetastatic renal cell carcinoma: is it really possible to define rational guidelines for post treatment follow up. Nat Clin Pract Oncol2006;3:200–213.
RouviereOBouvierRNegrierS. Nonmetastatic renal cell carcinoma: is it really possible to define rational guidelines for post treatment follow up. Nat Clin Pract Oncol2006;3:200–213.
)| false
MessingEM, ManolaJ, WildingG. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol2003;21:1214–1222.
MessingEMManolaJWildingG. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol2003;21:1214–1222.
)| false
ClarkJI, AtkinsMB, UrbaWJ. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a Cytokine Working Group randomized trial. J Clin Oncol2003;21:3133–3140.
ClarkJIAtkinsMBUrbaWJ. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a Cytokine Working Group randomized trial. J Clin Oncol2003;21:3133–3140.
)| false
FlaniganRC, SalmonSE, BlumensteinBA. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med2001;345:1655–1659.
FlaniganRCSalmonSEBlumensteinBA. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med2001;345:1655–1659.
)| false
MickischGH, GarinA, van PoppelH. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet2001;358:966–970.
MickischGHGarinAvan PoppelH. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet2001;358:966–970.
)| false
NegrierS, EscudierB, LassetC. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med1998;338:1273–1278.
NegrierSEscudierBLassetC. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med1998;338:1273–1278.
)| false
YangJC, SherryRM, SteinbergSM. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol2003;21:3127–3132.
YangJCSherryRMSteinbergSM. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol2003;21:3127–3132.
)| false
DutcherJP, FisherRI, WeissG. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am1997;3:157–162.
DutcherJPFisherRIWeissG. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am1997;3:157–162.
)| false
MotzerRJ, BasikJ, MurphyBA. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol2002;20:289–296.
MotzerRJBasikJMurphyBA. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol2002;20:289–296.
)| false
FaivreS, DelbaldoC, VeraK. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol2006;24:25–35.
FaivreSDelbaldoCVeraK. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol2006;24:25–35.
)| false
WilhelmSM, CarterC, TangL. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res2004;64:7099–7109.
WilhelmSMCarterCTangL. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res2004;64:7099–7109.
)| false
MooreM, HirteHW, SiuL. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol2005;16:1688–1694.
MooreMHirteHWSiuL. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol2005;16:1688–1694.
)| false
StrumbergD, RichlyH, HilgerRA. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol2005;23:965–972.
StrumbergDRichlyHHilgerRA. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol2005;23:965–972.
)| false
AwadaA, HendliszA, GilT. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer2005;92:1855–1861.
AwadaAHendliszAGilT. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer2005;92:1855–1861.
)| false
ClarkJW, EderJP, RyanD. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res2005;11:5472–5480.
ClarkJWEderJPRyanD. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res2005;11:5472–5480.
)| false
SzczylikT, DemkowM, StaehlerF. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J Clin Oncol2007;25(18S):5025.
SzczylikTDemkowMStaehlerF. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J Clin Oncol2007;25(18S):5025.
)| false
GibbonsJJ, DiscafaniC, PetersonR. The effect of CCI-779, a novel macrolide anti-tumor agent, on growth of human tumor cells in vitro and in nude mouse xenografts in vivo [abstract]. Proc Am Assoc Cancer Res1999;40:Abstract 301.
GibbonsJJDiscafaniCPetersonR. The effect of CCI-779, a novel macrolide anti-tumor agent, on growth of human tumor cells in vitro and in nude mouse xenografts in vivo [abstract]. Proc Am Assoc Cancer Res1999;40:Abstract 301.
)| false
YangJC, HaworthL, SherryRM. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med2003;349:427–434.
YangJCHaworthLSherryRM. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med2003;349:427–434.
)| false
EscudierB, PluzanskaA, KoralewskiP. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet2007;370:2103–2111.
EscudierBPluzanskaAKoralewskiP. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet2007;370:2103–2111.
)| false
StadlerWM, HalabiS, ErnstoffMS. A phase II study of gemcitabine (G) and capecitabine (C) in patients with metastatic renal cell cancer (mRCC): a report of Cancer and Leukemia Group B #90008 [abstract]. J Clin Oncol2004;22(Suppl 1):Abstract 4515.
StadlerWMHalabiSErnstoffMS. A phase II study of gemcitabine (G) and capecitabine (C) in patients with metastatic renal cell cancer (mRCC): a report of Cancer and Leukemia Group B #90008 [abstract]. J Clin Oncol2004;22(Suppl 1):Abstract 4515.
)| false
MotzerRJ, EscudierB, OudardS. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet2008;372:449–456.
MotzerRJEscudierBOudardS. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet2008;372:449–456.
)| false
BukowskiRM, EisenT, SzczylikC. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 5023.
BukowskiRMEisenTSzczylikC. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 5023.
)| false